BMJ Clin Evid 2015[]; 2015 (ä): ä PMIDC4429848show ga
Introduction: Anterior uveitis is rare, with an annual incidence of 12 per 100,000 population, although it is more common in Finland (annual incidence of 23/100,000), probably because of genetic factors such as high frequency of HLA-B27 in the population. It is often self-limiting but can, in some cases, lead to complications such as posterior synechiae, cataract, glaucoma, cystoid macular oedema, and chronic uveitis. Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of interventions on acute anterior uveitis? We searched: Medline, Embase, The Cochrane Library and other important databases up to August 2014 (BMJ Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). Results: We found 10 studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: corticosteroids (topical/eye drops, oral, subconjunctival injection), mydriatics, and non-steroidal anti-inflammatory drug eye drops.
free
free
free
BMJ+Clin+Evid 2015 ; 2015 (ä): ä
